New tumour destruction data for Prescient’s OmniCAR and CellPryme platforms
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR...
Prescient was pleased to present data on our cell therapies at the prestigious International Society...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive...
Prescient Therapeutics (ASX: PTX) -- a publicly listed oncology company developing targeted and cell therapies...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr...
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.